Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Quinacrine Hydrochloride

Phase 2

VVictoria Werth

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cutaneous Lupus Erythematosus (CLE)Recruiting

Cutaneous Lupus Erythematosus (CLE)Phase 2

Recruiting

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Cutaneous Lupus Erythematosus (CLE)

NCT07694336

Clinical

Trials by Indication[1]

Cutaneous Lupus Erythematosus (CLE)1 trial

A Randomized, Double-blind, Placebo-controlled Study of Quinacrine (QC) in Participants With Active Cutaneous Lupus Erythematosus (CLE), Including Subacute CLE (SCLE) and/or Discoid LE (DLE), With or Without Concurrent Systemic Manifestations

Recruiting·VVictoria Werth·Phase 2·NCT07694336·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Quinacrine Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Quinacrine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Victoria Werth company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: VVictoria Werth

Related News